DYAI Dyadic
- 1.489
- +0.059+4.09%
Dyadic News
Dyadic to Attend Industry and Investor Events in May
JUPITER, Fla., May 08, 2024 — Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address th
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
JUPITER, Fla., April 30, 2024 — Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture o
Dyadic International Files to Sell 3.35M Shares for Holders
Earnings Call Summary | Dyadic(DYAI.US) Q4 2023 Earnings Conference
The following is a summary of the Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript:Financial Performance:Dyadic reported a slight decrease in research and development revenue and lic
Recap: Dyadic International Q4 Earnings
Dyadic International (NASDAQ:DYAI) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:00 PM.Here's what investors need to know about the announcement.EarningsDyadic International misse
Dyadic International Q4 EPS $(0.08) Misses $(0.06) Estimate, Sales $686.53K Miss $800.00K Estimate
Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 14.29 percent decrease over losses
Dyadic International Announces Key Leadership Changes
Dyadic International GAAP EPS of -$0.24 Misses by $0.01, Revenue of $2.9M Misses by $0.15M
Press Release: Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic Reports 2023 Full Year Results and Recent Company Progress -- Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants -- Rep
Dyadic Says Patrick Lucy Named Board Chair; Joseph Hazelton Appointed COO
Dyadic International (DYAI) said Thursday that Michael Tarnok is stepping down as chair of its board and that current board member Patrick Lucy will succeed him. Tarnok will be a director until the en
Dyadic Intl Appoints Joseph Hazelton COO Effective Immediately >DYAI
Dyadic Intl Appoints Joseph Hazelton COO Effective Immediately >DYAI
Dyadic Intl Appoints Patrick Lucy Chairman >DYAI
Dyadic Intl Appoints Patrick Lucy Chairman >DYAI
Dyadic Intl: Tarnok Will Continue to Serve as a Director Until June>DYAI
Dyadic Intl: Tarnok Will Continue to Serve as a Director Until June>DYAI
Dyadic Intl Chairman Michael Tarnok to Step Down >DYAI
Dyadic Intl Chairman Michael Tarnok to Step Down >DYAI
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. • Shimmick (NASDAQ:SHIM) is estimated
Dyadic Reports 2023 Full Year Results and Recent Company Progress
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical s
Dyadic International's Earnings: A Preview
Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.Analysts estimate that Dyadic
Dyadic to Attend Industry Events in April
JUPITER, Fla., March 27, 2024 — Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address
Dyadic Publishes C1 Monoclonal Antibody In Nonhuman Primate Study In Nature Communications
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.
Analysis
Price Target
No Data
